|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Contraindications for video capsule endoscopy显示文摘Video capsule endoscopy(VCE) has been applied in the last 15 years in an increasing field of applications. Although many contraindications have been put into perspective, some precautions still have to be considered. Known stenosis of the gastrointestinal tract is a clear contraindication for VCE unless surgery is already scheduled or at least has been considered as an optional treatment modality. In patients with a higher incidence of stenosis, as in an established diagnosis of Crohn's disease, clinical signs of obstruction, prior radiation or surgical small bowel resection, a preceding test with the self-dissolving patency capsule can override this contraindication. Endoscopic placement of the capsule should be considered in patients with swallowing disorders to avoid aspiration. Esophageal or gastric motility disorders may require endoscopic capsule transport or application of prokinetics if the real-time viewer proofs delayed transit. In pregnant women, VCE should be restricted to urgent cases where diagnosis cannot be postponed after delivery, as data on safety are missing. There is theoretical and clinical evidence that patients with implanted cardiac devices such as a pacemaker, cardioverters or left heart assist devices, can safely undergo VCE in spite of still existing contraindication by manufacturers. Children from the age of 2 years have safely undergone VCE. Although video capsules are not proven safe with magnetic resonance imaging(MRI), first single cases of patients incidentally undergoing MRI with an incorporated capsule have been reported, showing susceptibility artifacts but no signs of clinical harm. | Dirk Bandorski Niehls Kurniawan Peter Baltes Reinhard Hoeltgen Matthias Hecker Dominik Stunder Martin Keuchel | 2016 | World Journal of Gastroenterology2016，22，45： | 2 |
| 2 | Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentration of procalcitonin, protein complement 3a, and interleukin- 6显示文摘 | Selberg O Hecker H Martin M | 2000 | Crit Care Med2000，28，： | 1 |
| 3 | Discrimination of sepsisand systemic inflammatory response syndroxne by determinationof circulating plasma concentration of procalcitooin, protein com-plment and interleakin 显示文摘 | Selberg 0 Hecker H Martin M | 2000 | Crit Care Med2000，28，： | 1 |
| 4 | Discrimination of sepsis and systemic inflammatory response ayndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a,and interleukin- 6显示文摘 | Selberg Oliver Hecker Hartmut Martin Michael | 2000 | Crit Care Med2000，28，8： | 1 |
| 5 | Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6显示文摘 | Selberg O Hecker H Martin M | 2000 | Crit Care Medl2000，28，8： | 1 |
| 6 | Discrimination of sepsisand systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalci- tonin,protein complement 3a,and rttterleukin-6 显示文摘 | Selberg O Hecker H Martin M etal | 2010 | Crit Care Med2010，28，7： | 1 |
| 7 | Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin,protein complement 3a,and interleukin-6显示文摘 | Selberg O Hecker H Martin M | | 0，，： | 1 |
| 8 | Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentration of procalcitonin,protein complment and interleakin显示文摘 | Selberg O Hecker H Martin M | 2000 | Crit Care Med2000，28，： | 1 |
| 9 | Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin,protein complement 3a,and interleukin-6显示文摘 | Selberg O Hecker H Martin M | 2000 | Crit Care Med2000，28，8： | 1 |
| 10 | Discrimination of sepsis and syste nile inflanmmatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin 6显示文摘 | Selberq O Hecker H Martin M | 2000 | Crit Care Meal2000，28，8： | 1 |
| 11 | Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6显示文摘 | Selberg N Hecker H Martin M | 2000 | Crit Care Med2000，28，8： | 1 |
| 12 | Discrimination of sepsis and systemic inflammatory reaponse syngrome by determination of circulating plasma concentration of procalcitonin protein complment 3a, and interleakin-6 显示文摘 | Selberg O Hecker H Martin M | 2000 | Crie Care Med2000，28，8： | 1 |
| 13 | Discrimination of sepsis and systemic inflammatory reaponse syndrome by determination of circulating plasma concentration of pro calcitonin, protein complment 3a, and interleakin- 6 显示文摘 | Selberg O Hecker H Martin M | 2000 | CrieCare Med2000，28，27： | 1 |
| 14 | Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin - 6 显示文摘 | Selberg O Hecker H Martin M | 2000 | Crit Care Med2000，28，7： | 1 |
| 15 | Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of proealcitonin,protein complement 3a ,and interlcukin-6显示文摘 | Selberg O Hecker H Martin M et at | 2000 | Critical Care Med2000，28，8： | 1 |
| 16 | Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6显示文摘 | Selberg O Hecker H Martin M | 2000 | Crit Care Med2000，28，8： | 1 |
| 17 | Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of proealcitonin, protein com- plement 3a, and interleukin - 6 显示文摘 | Selberg O Hecker H Martin M | 2000 | Crit Care Med2000，28，8： | 1 |
| 18 | 在AI时代快速构建竞争优势显示文摘人工智能的“类人”潜力正逐步变成现实,机器开始具备本属于人类的能力.是时候该问问:商业领袖如何利用人工智能,充分发挥人与机器的独特优势? | Philipp Gerbert Jan Justus Martin Hecker | 2017 | 机器人产业2017，，5： | 1 |
| 19 | Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulation plasma concentrations of procalcitonin,protein complement 3a, and interleukin-6显示文摘 | Selberg O Hecker H Martin M | 2000 | Crit Care Med2000，28，8： | 1 |
| 20 | Discrimination of sepsis and systemic inflammatory responsesyndrome by determination of circulating plasma concentrations of procalcitonin,protein complement 3a,and interleukin-6显示文摘 | Selberg O Hecker H Martin M | | 0，，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员